Show simple item record

dc.contributor.authorAkram, Javed
dc.contributor.authorSaeed Khan, Khalid
dc.date.accessioned2021-01-27T09:21:59Z
dc.date.available2021-01-27T09:21:59Z
dc.date.issued2020
dc.identifier.citationAkram, J., Azhar, S., Shahzad, M. et al. Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial. Trials 21, 702 (2020). https://doi.org/10.1186/s13063-020-04616-4es_ES
dc.identifier.urihttp://hdl.handle.net/10481/66053
dc.description.abstractObjectives: To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus (COVID-19) nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).es_ES
dc.description.sponsorshipUniversity of Health Sciences (UHS) Lahore, Punjab, Pakistanes_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectCOVID-19es_ES
dc.subjectRandomised controlled triales_ES
dc.subjectProtocoles_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectHydroxychloroquinees_ES
dc.subjectAzithromycines_ES
dc.subjectOseltamivires_ES
dc.subjectMulti-centeres_ES
dc.subjectAdaptivees_ES
dc.subjectRandomizationes_ES
dc.titlePakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1186/s13063-020-04616-4


Files in this item

[PDF]
[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España